MedTrace Logo

CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell Malignancies

NCT04156178 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2019-11-12

No results posted yet for this study

Summary

This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of CD20-CD19 cCAR in patients with relapsed and/or refractory B cell malignancies.

Conditions

  • B Cell Lymphoma
  • B Cell Leukemia

Interventions

BIOLOGICAL

CD20-CD19 cCAR T cells

CD20-CD19 cCAR T cells administered to patients, will be either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy

Sponsors & Collaborators

  • Peking University Shenzhen Hospital

    collaborator OTHER

  • Chengdu Military General Hospital

    collaborator OTHER

  • iCAR Bio Therapeutics Ltd.

    collaborator INDUSTRY

  • iCell Gene Therapeutics

    lead INDUSTRY

Principal Investigators

  • Hongyu Zhang, MD, PhD · Peking University Shenzhen Hospital

  • Fang Liu, MD, PhD · Chengdu Military General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-01
Primary Completion
2020-09-30
Completion
2020-09-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04156178 on ClinicalTrials.gov